Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INAB IN8bio	$2.23 +1.8%	$2.23	$1.98 ▼ $16.86	$10.12M	0.01	163,502 shs	29,903 shs
LIPO Lipella Pharmaceuticals	$0.59 0.0%	$0.85	$0.55 ▼ $7.31	$2.74M	-0.1	868,729 shs	982 shs
SNSE Sensei Biotherapeutics	$8.10 -0.1%	$8.04	$5.00 ▼ $17.40	$10.21M	0.26	65,157 shs	10,568 shs
SONN Sonnet BioTherapeutics	$3.61 +0.6%	$3.67	$1.08 ▼ $19.30	$24.38M	1.04	1.61 million shs	321,484 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INAB IN8bio	-3.10%	-8.37%	-10.25%	-49.27%	-86.36%
LIPO Lipella Pharmaceuticals	+0.51%	+0.36%	-5.39%	-79.99%	-85.73%
SNSE Sensei Biotherapeutics	+2.18%	-0.67%	+17.69%	+32.93%	-30.94%
SONN Sonnet BioTherapeutics	+3.46%	+7.16%	-10.03%	+201.68%	-40.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INAB IN8bio	3.5167 of 5 stars	3.5	5.0	0.0	0.0	2.3	1.7	1.3
LIPO Lipella Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNSE Sensei Biotherapeutics	4.2787 of 5 stars	3.7	3.0	0.0	4.8	0.6	1.7	1.3
SONN Sonnet BioTherapeutics	3.0053 of 5 stars	3.5	4.0	0.0	0.0	1.3	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INAB IN8bio	3.00	Buy	$180.00	7,971.75% Upside
LIPO Lipella Pharmaceuticals	0.00	N/A	N/A	N/A
SNSE Sensei Biotherapeutics	3.33	Buy	$55.00	579.01% Upside
SONN Sonnet BioTherapeutics	3.00	Buy	$20.00	454.02% Upside

Current Analyst Ratings Breakdown

Latest LIPO, INAB, SNSE, and SONN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/5/2025	SNSE Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/2/2025	SNSE Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$100.00

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INAB IN8bio	N/A	N/A	N/A	N/A	$6.00 per share	N/A
LIPO Lipella Pharmaceuticals	$536.36K	5.11	N/A	N/A	$1.59 per share	0.37
SNSE Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$30.52 per share	N/A
SONN Sonnet BioTherapeutics	$1M	24.38	N/A	N/A	($0.71) per share	-5.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INAB IN8bio	-$30.44M	-$9.11	N/A	N/A	N/A	N/A	-184.97%	-126.75%	11/11/2025 (Estimated)
LIPO Lipella Pharmaceuticals	-$5.02M	-$3.43	N/A	∞	N/A	-988.83%	-224.08%	-172.88%	N/A
SNSE Sensei Biotherapeutics	-$30.16M	-$21.31	N/A	N/A	N/A	N/A	-72.13%	-61.35%	11/13/2025 (Estimated)
SONN Sonnet BioTherapeutics	-$7.44M	N/A	0.00	∞	N/A	N/A	-4,646.10%	-342.21%	N/A

Latest LIPO, INAB, SNSE, and SONN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q3 2025	SONN Sonnet BioTherapeutics	-$0.49	-$0.95	-$0.46	-$0.95	N/A	N/A
8/7/2025	Q2 2025	INAB IN8bio	-$1.50	-$1.24	+$0.26	-$1.24	N/A	N/A
8/5/2025	Q2 2025	SNSE Sensei Biotherapeutics	-$6.20	-$3.91	+$2.29	-$3.91	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INAB IN8bio	N/A	N/A	N/A	N/A	N/A
LIPO Lipella Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SNSE Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A
SONN Sonnet BioTherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INAB IN8bio	0.01	7.03	7.03
LIPO Lipella Pharmaceuticals	N/A	6.21	6.21
SNSE Sensei Biotherapeutics	N/A	7.64	7.64
SONN Sonnet BioTherapeutics	N/A	0.26	0.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INAB IN8bio	92.05%
LIPO Lipella Pharmaceuticals	74.31%
SNSE Sensei Biotherapeutics	10.50%
SONN Sonnet BioTherapeutics	9.45%

Insider Ownership

Company	Insider Ownership
INAB IN8bio	9.50%
LIPO Lipella Pharmaceuticals	32.11%
SNSE Sensei Biotherapeutics	23.20%
SONN Sonnet BioTherapeutics	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INAB IN8bio	20	4.54 million	4.11 million	Not Optionable
LIPO Lipella Pharmaceuticals	4	4.62 million	3.03 million	Not Optionable
SNSE Sensei Biotherapeutics	40	1.26 million	968,000	Not Optionable
SONN Sonnet BioTherapeutics	10	6.75 million	6.62 million	Not Optionable

LIPO, INAB, SNSE, and SONN Headlines

Recent News About These Companies

Biotechs Turn to Digital Coins, Crypto to Boost Stock Prices

August 25 at 3:38 PM | msn.com

Sonnet BioTherapeutics (NASDAQ:SONN) Upgraded at Wall Street Zen

August 19, 2025 | americanbankingnews.com

Sonnet Biotherapeutics Faces Earnings Volatility with New HYPE Treasury Strategy and Accounting Standards

August 15, 2025 | msn.com

Sonnet Releases Virtual Investor "What This Means" Segment

August 11, 2025 | globenewswire.com

This Cancer Biotech Company Is Making a Big Bet on the HYPE Crypto. Should You Buy Its Stock Here?

August 6, 2025 | msn.com

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

August 4, 2025 | globenewswire.com

Beyond BTC and ETH: The Companies Turning to Alternative Crypto Treasury Assets

August 2, 2025 | msn.com

Sonnet BioTherapeutics Appoints Interim CEO Raghu Rao

August 1, 2025 | tipranks.com

Solana-based treasury model goes global as DeFi Development launches franchise

July 17, 2025 | msn.com

WLFI tokens to become tradable after World Liberty holders’ vote

July 17, 2025 | msn.com

Hyperliquid Strategies Inc. plan for $583M treasury boosts HYPE price

July 16, 2025 | cointelegraph.com

Sonnet BioTherapeutics Merges in $888M Deal to Launch Hyperliquid Strategies and HYPE Treasury

July 15, 2025 | thecurrencyanalytics.comT

Sonnet BioTherapeutics Stock Jumps 82% After Deal With Rorschach I: Retail Stays Exuberant

July 15, 2025 | msn.com

Public Firm Sonnet BioTherapeutics to Launch HyperLiquid Treasury in New Deal

July 14, 2025 | coinspeaker.com

Sonnet BioTherapeutics Shares Climb After Plan to Transfer Into Public Crypto Treasury Co.

July 14, 2025 | marketwatch.com

Why did Sonnet BioTherapeutics (SONN) Shares Gain over 200% in Premarket Trading?

July 14, 2025 | tokenist.comT

Hyperliquid Price Forecast: HYPE eyes gains following Sonnet BioTherapeutics' rebrand

July 14, 2025 | fxstreet.com

HYPE coin price up 200%, Sonnet BioTherapeutics merges into Hyperliquid Strategies

July 14, 2025 | msn.com

Massive deal sends biotech stock rallying 367%

July 14, 2025 | msn.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)

July 14, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIPO, INAB, SNSE, and SONN Company Descriptions

IN8bio NASDAQ:INAB

$2.23 +0.04 (+1.83%)

Closing price 03:58 PM Eastern

Extended Trading

$2.24 +0.02 (+0.67%)

As of 04:10 PM Eastern

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Lipella Pharmaceuticals NASDAQ:LIPO

$0.59 0.00 (-0.03%)

As of 02:38 PM Eastern

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

Sensei Biotherapeutics NASDAQ:SNSE

$8.10 -0.01 (-0.12%)

Closing price 03:58 PM Eastern

Extended Trading

$8.43 +0.33 (+4.07%)

As of 04:04 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Sonnet BioTherapeutics NASDAQ:SONN

$3.61 +0.02 (+0.56%)

Closing price 04:00 PM Eastern

Extended Trading

$3.52 -0.09 (-2.63%)

As of 05:24 PM Eastern

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time